@article {7515,
	title = {Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma},
	journal = {Expert Review of Anticancer Therapy},
	volume = {15},
	year = {2015},
	note = {Cited By :13Export Date: 21 February 2017},
	month = {2015},
	pages = {737 - 748},
	abstract = {Outcomes for patients with multiple myeloma (MM) have improved significantly over the past decade. Despite these advances, MM remains incurable and an unmet medical need remains for patients who are relapsed and/or refractory. Panobinostat is a potent, oral pan-deacetylase inhibitor that elicits anti-myeloma activity through epigenetic modulation of gene expression and disruption of protein metabolism. Preclinical data demonstrated that panobinostat has synergistic effects on myeloma cells when combined with bortezomib and dexamethasone. In a Phase III clinical trial evaluating bortezomib and dexamethasone in combination with panobinostat or placebo in patients with relapsed or relapsed and refractory MM (PANORAMA 1), panobinostat led to a significant increase in median progression-free survival. Panobinostat is currently under regulatory review with a recent accelerated approval granted for the treatment of relapsed disease, in which both bortezomib and immunomodulatory drugs have failed. Here, we summarize the preclinical, pharmacokinetic and clinical data for panobinostat in MM. {\textcopyright} 2015 Informa UK, Ltd.},
	keywords = {bortezomib, deacetylase inhibitors, multiple myeloma, panobinostat, treatment of relapsed and refractory disease},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84933518228\&doi=10.1586\%2f14737140.2015.1047770\&partnerID=40\&md5=b86ffc272cb5cb6d6176b5120b37bcdc},
	author = {Richardson, P.G. and Laubach, J.P. and Lonial, S. and Moreau, P. and Yoon, S.-S. and Hungria, V.T. and Dimopoulos, M.A. and Beksac, M. and Alsina, M. and San-Miguel, J.F.}
}
